ALMS

Alumis (ALMS)

About Alumis (ALMS)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Details

Daily high
$11.30
Daily low
$8.43
Price at open
$8.50
52 Week High
$11.30
52 Week Low
$2.76
Market cap
1.2B
Dividend yield
0.00%
Volume
4.4M
Avg. volume
1.5M
P/E ratio
-2.88

Alumis News

Details

Daily high
$11.30
Daily low
$8.43
Price at open
$8.50
52 Week High
$11.30
52 Week Low
$2.76
Market cap
1.2B
Dividend yield
0.00%
Volume
4.4M
Avg. volume
1.5M
P/E ratio
-2.88